Published in

Taylor and Francis Group, OncoImmunology, 4(3), p. e28498

DOI: 10.4161/onci.28498

Links

Tools

Export citation

Search in Google Scholar

Immune response markers in sentinel nodes may predict melanoma progression

Journal article published in 2014 by Monica Rodolfo ORCID, Chiara Castelli, Licia Rivoltini
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

We recently reported that variable expression of immune-response genes distinguishes tumor positive sentinel nodes in melanoma patients with malignant progression from those with non-progressing disease. Our results depict sentinel nodes as sites in which immune functions are associated with metastatic disease and identify CD30 as a host immune-related cancer prognostic marker and potential therapeutic target.